Reflexion BGRT

We’re lighting up cancer.

By combining radiotherapy and PET-CT in a novel way, we can find and treat cancer using its own emissions.

See Clinical Evidence

Guiding radiotherapy from inside the body.

RefleXion BgRT is the first to utilize the cancer itself to guide radiation delivery - even in tumors that are moving - envisioning a leap forward in the ongoing goal of managing motion, reducing margins and diminishing toxicity, so that one-day multiple tumors can be treated in parallel during the same session.

Download Whitepaper

Metastatic disease has met its match.

Most patients with stage four cancer are not considered candidates for definitive radiotherapy due to the challenge of treating multiple tumors. RefleXion seeks to change that, with BgRT meant to enable same-session treatment of multiple tumors.

Unlock the potential
of PET tracers.

Some cancers are harder to spot than others. The RefleXion X1 is the only machine with the potential to use disease-specific tracers to see and treat hard-to-find tumors.

The treatment trifecta.

For many patients, the best treatment plan is a combination of multiple therapies. RefleXion BgRT was envisioned with advanced stage cancer patients in mind. When added to chemotherapy, immunotherapy and targeted drugs, it may help to improve outcomes.

Turning cancer into
its own worst enemy

The RefleXion X1 marries PET-CT, a proven modality for visualizing cancer, with radiation, one of the most effective ways of treating cancer.

Discover the RefleXion X1 machine.

A closer look at the proprietary technologies that combine to create our game-changing approach to cancer treatment.

What is BgRT?

BgRT lights up and treats cancer in real time.

RefleXion’s BgRT uses PET – the gold standard in cancer imaging – to solve the conundrum of tumor tracking. BgRT aims to remove the uncertainty of guiding radiation delivery using images taken days before treatment. With PET emissions guiding treatment, the cancer itself acts as a fast, biological fiducial continuously signaling its location even during motion.

As the PET tracer accumulates in the tumor, a series of positron annihilation events occur resulting in the emission of two photons almost 180 degrees to each other.  Their source – the tumor – can be localized along this straight line of coincidence, called a line of response, or LOR. The PET arcs on the RefleXion X1 machine detect the LORs and use that location information for treatment delivery. This real-time response by the LINAC to detected PET emissions is the fundamental principle of BgRT.

Go to Video

Metastatic or stage four cancer.

Radiotherapy envisioned from the ground up to treat advanced-stage cancer.

Most patients with stage four cancer are not considered candidates for definitive radiotherapy because existing technology can’t efficiently track and treat multiple tumors. As well, treatment plans are not based on the real-time location of the tumor, but rather on anatomic surrogates or other implanted fiducials. To combat these limitations, complexity is added to both treatment planning and patient setup and margins of healthy tissue are added to the gross tumor volume (GTV) to a degree that conventional radiotherapy is not feasible for metastatic disease.

Simply put, there is no better fiducial than the tumors themselves from which to plan and deliver treatment. With BgRT, we eliminate the burden of fiducials or gating. And using tracked delivery, we avoid irradiating an entire ITV. With these advances, RefleXion Therapy aims to enable efficient treatment of multiple tumors in parallel during a single session. The machine bases radiotherapy delivery on precise, real-time tumor locations, so the treatment plan can include multiple tumors during the same fraction, a potential game-changing advance for metastatic disease. RefleXion’s patented BgRT delivers high doses of radiation for a powerful impact to the tumor, while sparing the surrounding healthy tissue to enable radiotherapy for people with advanced cancers for the first time.

Go to Video

Disease-specific radiotracers

RefleXion sees tumors and their motion that others can't.

PET scanners provide enormous benefit in locating hard-to-find tumors using disease-specific radiotracers for tumor diagnosis and staging, but wouldn’t it be ideal if it could then deliver treatment? Introducing the RefleXion X1, finally a machine that aims to do both. RefleXion’s BgRT has the potential to one day elevate the performance of PET tracers from a diagnostic tool to precise therapeutic guidance.

The RefleXion machine is compatible with FDG and is poised to take advantage  of the rapidly growing ecosystem of radiotracers. Some tracers work by identifying biomarker antigens, while others depict metabolic activity, and still others probe the immune system itself. Regardless of the mechanism of action, all positron-emitting tracers within the cancer cells produce gamma-rays via annihilation to produce lines of response or emissions. And the RefleXion X1 is the only machine capable of using emissions to see and treat tumors.

Go to Video

Changing the standard of care requires clinical evidence.

RefleXion Therapy is a vastly different approach to radiotherapy and so is our belief about evidence creation. Partnering with our Consortium members, we have designed a robust clinical trial program to prove the efficacy of BgRT.

View Bibliography

Feedback
and
Inquiries.

Let us tell you more.

Contact Us

Sign up for our
latest news and information.

Stay up to date.

Sign Up